January 11, 2015 | Protalix Biotherapeutics announced positive results in the trials of a drug for the treatment of Fabry Disease, after which the company’s shares saw a 12 percent spike. The results on 3 patients with Fabry Disease, a rare lysosomal storage disease, demonstrated significant clinical effectiveness, even at a low dosage of the drug. The results showed what the company reports to be a 78.8 percent decrease in the effect of pain on a patient’s daily functions, as well as stable heart and kidney function. The complete results of the study are set to be published by the close of 2015. Protalix was founded in 1993 by Yoseph Shaaltiel and is currently headed by CEO and President David Aviezer.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
![](https://nocamels.com/wp-content/uploads/2018/02/INSIGHTEC-350x180.jpg)
Israeli Ultrasound Creator Collaborating On Neuroscience R&D In US
September 05, 2024
![The Weizmann Institute of Science. Photo via the Weizmann Institute of Science](https://nocamels.com/wp-content/uploads/2018/07/weizmann-350x252.jpg)
Weizmann In World’s Top 10 For Biomedical And Overall Research
September 05, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/Depositphotos_75148477_L-350x228.jpg)
Israeli NGO Begins New Mental Health Training In Ukraine
September 04, 2024
![](https://nocamels.com/wp-content/uploads/2024/09/17123254699_79ff768811_ks-350x213.jpg)
Nonprofit Launches Loans For Stricken Northern Israel Businesses
September 04, 2024
Facebook comments